AKAN vs NIVF

AKAN exhibits severe financial distress, evidenced by a Piotroski F-Score of 3/9 (indicating weak operational health) and a lack of an Altman Z-Score, which raises red flags for potential bankruptcy risk. The company is unprofitable with negative margins across all key metrics, including a staggering -266.31% profit margin and -60.86% ROE. Despite a low Price/Book of 0.04 and a Graham Number of $281.01, the stock trades at $0.82—well below fair value—due to extreme operational failure and lack of sustainable growth. The 52-week price range shows a collapse from $46.45 to $0.81, reflecting a 100% decline over five years and confirming deep investor skepticism.

NIVF exhibits a catastrophic price collapse (-99.8% over 1 year) and severe operational dysfunction. While the Piotroski F-Score of 5/9 suggests baseline stability, this is heavily skewed by a non-operating profit spike, as evidenced by a 209.03% profit margin contrasted against a disastrous -349.13% operating margin. The company is fundamentally unable to generate profit from its core medical care facilities. The massive discrepancy between the current price ($2.19) and the single analyst's target price ($900) indicates a complete breakdown in valuation reliability.